• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kelch-like 蛋白 5 介导的赖氨酸 183 泛素化促进鞘氨醇激酶 1 的蛋白酶体降解。

Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.

机构信息

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.

Adelaide Medical School, University of Adelaide, Adelaide, Australia.

出版信息

Biochem J. 2019 Nov 15;476(21):3211-3226. doi: 10.1042/BCJ20190245.

DOI:10.1042/BCJ20190245
PMID:31652307
Abstract

Sphingosine kinase 1 (SK1) is a signalling enzyme that catalyses the phosphorylation of sphingosine to generate the bioactive lipid sphingosine 1-phosphate (S1P). A number of SK1 inhibitors and chemotherapeutics can induce the degradation of SK1, with the loss of this pro-survival enzyme shown to significantly contribute to the anti-cancer properties of these agents. Here we define the mechanistic basis for this degradation of SK1 in response to SK1 inhibitors, chemotherapeutics, and in natural protein turnover. Using an inducible SK1 expression system that enables the degradation of pre-formed SK1 to be assessed independent of transcriptional or translational effects, we found that SK1 was degraded primarily by the proteasome since several proteasome inhibitors blocked SK1 degradation, while lysosome, cathepsin B or pan caspase inhibitors had no effect. Importantly, we demonstrate that this proteasomal degradation of SK1 was enabled by its ubiquitination at Lys183 that appears facilitated by SK1 inhibitor-induced conformational changes in the structure of SK1 around this residue. Furthermore, using yeast two-hybrid screening, we identified Kelch-like protein 5 (KLHL5) as an important protein adaptor linking SK1 to the cullin 3 (Cul3) ubiquitin ligase complex. Notably, knockdown of KLHL5 or Cul3, use of a cullin inhibitor or a dominant-negative Cul3 all attenuated SK1 degradation. Collectively this data demonstrates the KLHL5/Cul3-based E3 ubiquitin ligase complex is important for regulation of SK1 protein stability via Lys183 ubiquitination, in response to SK1 inhibitors, chemotherapy and for normal SK1 protein turnover.

摘要

丝氨酸棕榈酰转移酶激酶 1(SK1)是一种信号酶,能够催化鞘氨醇磷酸化为具有生物活性的鞘氨醇 1-磷酸(S1P)。许多 SK1 抑制剂和化疗药物可以诱导 SK1 的降解,这种促生存酶的丧失被证明对这些药物的抗癌特性有显著贡献。在这里,我们定义了 SK1 抑制剂、化疗药物和自然蛋白周转对 SK1 降解的机制基础。使用可诱导的 SK1 表达系统,使我们能够独立于转录或翻译效应评估预先形成的 SK1 的降解,我们发现 SK1 主要通过蛋白酶体降解,因为几种蛋白酶体抑制剂阻止了 SK1 的降解,而溶酶体、组织蛋白酶 B 或泛半胱天冬酶抑制剂没有影响。重要的是,我们证明了 SK1 的这种蛋白酶体降解是通过其在赖氨酸 183 处的泛素化来实现的,这似乎是由 SK1 抑制剂诱导的 SK1 结构中该残基周围的构象变化所促进的。此外,我们使用酵母双杂交筛选鉴定 Kelch 样蛋白 5(KLHL5)作为一种重要的蛋白质衔接物,将 SK1 与 cullin 3(Cul3)泛素连接酶复合物连接起来。值得注意的是,KLHL5 或 Cul3 的敲低、使用 cullin 抑制剂或显性负 Cul3 都减弱了 SK1 的降解。总的来说,这些数据表明 KLHL5/Cul3 基 E3 泛素连接酶复合物通过赖氨酸 183 泛素化对 SK1 蛋白稳定性的调节很重要,这是对 SK1 抑制剂、化疗和正常 SK1 蛋白周转的反应。

相似文献

1
Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.Kelch-like 蛋白 5 介导的赖氨酸 183 泛素化促进鞘氨醇激酶 1 的蛋白酶体降解。
Biochem J. 2019 Nov 15;476(21):3211-3226. doi: 10.1042/BCJ20190245.
2
Selective proteasomal degradation of the B'β subunit of protein phosphatase 2A by the E3 ubiquitin ligase adaptor Kelch-like 15.E3 泛素连接酶接头 Kelch-like 15 对蛋白磷酸酶 2A 的 B'β 亚基的选择性蛋白酶体降解。
J Biol Chem. 2012 Dec 21;287(52):43378-89. doi: 10.1074/jbc.M112.420281. Epub 2012 Nov 7.
3
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.Cullin 3-SPOP泛素E3连接酶促进组蛋白去乙酰化酶6(HDAC6)的多聚泛素化和降解。
Oncotarget. 2017 Jul 18;8(29):47890-47901. doi: 10.18632/oncotarget.18141.
4
Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.鞘氨醇激酶抑制剂SKi或ABC294640可通过蛋白酶体降解鞘氨醇激酶1并抑制二氢神经酰胺去饱和酶,从而诱导雄激素非依赖性LNCaP-AI前列腺癌细胞生长停滞。
Oncotarget. 2016 Mar 29;7(13):16663-75. doi: 10.18632/oncotarget.7693.
5
Rotavirus NSP1 Associates with Components of the Cullin RING Ligase Family of E3 Ubiquitin Ligases.轮状病毒NSP1与E3泛素连接酶的Cullin RING连接酶家族的组分相关联。
J Virol. 2016 Jun 10;90(13):6036-48. doi: 10.1128/JVI.00704-16. Print 2016 Jul 1.
6
Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.丝氨酸剥夺时需要下调鞘氨醇激酶 1 以适应环境。
FASEB J. 2021 Feb;35(2):e21284. doi: 10.1096/fj.202001814RR.
7
The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.鞘氨醇激酶 1 抑制剂 2-(对羟苯胺基)-4-(对氯苯基)噻唑诱导哺乳动物细胞中鞘氨醇激酶 1 的蛋白酶体降解。
J Biol Chem. 2010 Dec 10;285(50):38841-52. doi: 10.1074/jbc.M110.127993. Epub 2010 Oct 6.
8
Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P.缺氧时间较短可上调鞘氨醇激酶 1,并通过 S1P 增加动脉对鞘氨醇 1-磷酸(S1P)的舒张作用。
J Pharmacol Exp Ther. 2019 Oct;371(1):63-74. doi: 10.1124/jpet.119.257931. Epub 2019 Aug 1.
9
Dual gain and loss of cullin 3 function mediates familial hyperkalemic hypertension.Cullin 3 功能的双重增益和缺失导致家族性高钾血症性高血压。
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1006-F1018. doi: 10.1152/ajprenal.00602.2017. Epub 2018 Jun 13.
10
FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.FTY720 和(S)-FTY720 乙烯膦酸酯抑制人肺动脉平滑肌细胞、乳腺癌和雄激素非依赖性前列腺癌细胞中的鞘氨醇激酶 1 并促进其蛋白酶体降解。
Cell Signal. 2010 Oct;22(10):1536-42. doi: 10.1016/j.cellsig.2010.05.022. Epub 2010 Jun 4.

引用本文的文献

1
Molecular Mechanisms of Perivascular Macrophages in Alzheimer's Disease: Insights from Single-Cell Sequencing and Mendelian Randomization.阿尔茨海默病中血管周围巨噬细胞的分子机制:来自单细胞测序和孟德尔随机化的见解
Cell Mol Neurobiol. 2025 Jul 7;45(1):65. doi: 10.1007/s10571-025-01590-w.
2
KLHL5 Contributes to Colorectal Cancer Cell Survival by Promoting Cell Cycle Progression and Suppressing Apoptotic Cell Death.KLHL5通过促进细胞周期进程和抑制凋亡性细胞死亡来促进结肠癌细胞存活。
Cancer Sci. 2025 Sep;116(9):2444-2456. doi: 10.1111/cas.70108. Epub 2025 Jul 1.
3
Implication of KLHL Gene Family Member KLHL5 in Colorectal Cancer Progression and Prognosis.
KLHL基因家族成员KLHL5在结直肠癌进展和预后中的意义
Cancer Sci. 2025 Sep;116(9):2580-2591. doi: 10.1111/cas.70107. Epub 2025 Jun 12.
4
Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.癌症免疫编辑及对肿瘤坏死因子-α免疫疗法耐药中靶向鞘脂网络的信号争议与未来治疗前景
Cell Commun Signal. 2024 May 2;22(1):251. doi: 10.1186/s12964-024-01626-6.
5
Type 1 diabetes risk genes mediate pancreatic beta cell survival in response to proinflammatory cytokines.1型糖尿病风险基因介导胰腺β细胞在促炎细胞因子作用下的存活。
Cell Genom. 2022 Nov 11;2(12):100214. doi: 10.1016/j.xgen.2022.100214. eCollection 2022 Dec 14.
6
The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.鞘氨醇 1-磷酸受体 2/4 拮抗剂 JTE-013 会对鞘脂代谢产生非靶点作用。
Sci Rep. 2022 Jan 10;12(1):454. doi: 10.1038/s41598-021-04009-w.
7
Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.丝氨酸剥夺时需要下调鞘氨醇激酶 1 以适应环境。
FASEB J. 2021 Feb;35(2):e21284. doi: 10.1096/fj.202001814RR.
8
KLHL5 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Gastric Cancer.KLHL5是一种与预后相关的生物标志物,且与胃癌中的免疫浸润相关。
Front Mol Biosci. 2020 Dec 10;7:599110. doi: 10.3389/fmolb.2020.599110. eCollection 2020.
9
A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes.一种新型选择性鞘氨醇激酶 2 抑制剂 HWG-35D 通过阻断初始 CD4 T 淋巴细胞向 Th17 分化改善咪喹莫特诱导的银屑病模型的严重程度。
Int J Mol Sci. 2020 Nov 8;21(21):8371. doi: 10.3390/ijms21218371.
10
Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.可成药的神经酰胺代谢途径:实验模型与临床机遇
Adv Exp Med Biol. 2020;1274:101-135. doi: 10.1007/978-3-030-50621-6_6.